Spring 2025 funding cycle: Applications available until Monday, March 3.
- Call opens: Thursday, January 30, 2025
- Deadline: Monday March 3, 2025 (2:00 pm PST)
- Funding results: Available before end of May 2025
Amount available: $50,000 in direct costs for 1 year
Apply through the UCSF Resource Allocation Program (RAP) portal
The CFAR Mentored Scientist Award (our primary award program) is a mentoring and training grant targeted toward early stage (either at a senior stage of clinical or postdoctoral training or junior faculty) investigators at UCSF or affiliated partner institutes in the conduct of an HIV research project. These awards are designed to acquire preliminary data and research skills to prepare investigators for a future grant effort. Applicants for this award must indicate a faculty research mentor(s) who will commit to guiding the applicant throughout the duration of the proposed project.
Designation of Mentor
All Mentored award applications from individuals at the Assistant Professor level or below require an HIV research mentor. Mentors can, but are not required to, have supervisory authority over the applicant. CFAR requires your research mentor’s support to advise and guide the research portion of your application before submitting it to RAP.
Of high interest to CFAR are investigations ranging from basic pathogenesis to clinical outcomes in the research areas of HIV/aging and inflammation, latency, cure, vaccines, co-infections, HIV in women, implementation science, and research related to HIV-infected and HIV-impacted Bay Area populations. Projects must be within NIH’s HIV/AIDS research high or medium priority areas. Projects in closely related areas (e.g. TB, HCV, drug use, etc.) must be clearly linked to HIV in order to be eligible for CFAR funding.
The award amount is $50,000 in direct costs for one year.
CFAR requests that applicants review the NIAID HIV Language Guide as they prepare their proposals so that they can follow best practices on language for communicating respectfully about HIV and related topics, including the use of person-first, non-stigmatizing language. Please contact us if you have any questions about this request.
For more detailed information about this RFA, please see the RAP Portal.
To see examples of previously funded projects, see the list below.
Mentored Science Awardees
128 Awards
-
Evaluating the magnitude and durability of the vaccine-induced SARS-CoV-2 immune response in people with and without HIV infection
Evaluating the magnitude and durability of the vaccine-induced SARS-CoV-2 immune response in people with and without HIV infection
Abstract
-
Relationship between Kynurenine Pathway and TB-specific Th17 responses in People with HIV and Latent Tuberculosis Infection
Relationship between Kynurenine Pathway and TB-specific Th17 responses in People with HIV and Latent Tuberculosis Infection
Abstract
Tuberculosis (TB) remains the leading cause of death among people with HIV (PWH) globally and even among those with high CD4 counts during ART-mediated viral suppression. Evidence from animal studies indicate that interleukin (IL)-17 producing T cells (TH17) are likely beneficial in host immune response to Mycobacterium tuberculosis infection. TH17 cells are also important in HIV infection as loss of TH17 cells likely contributes to progression to AIDS through breakdown in mucosal immunity.
-
Targeting Viral Reservoirs through PET-Informed Dosing of Curative Agents
Targeting Viral Reservoirs through PET-Informed Dosing of Curative Agents
Abstract
Development of robust and validated methods to quantify tissue-specific drug exposure and the size of the HIV reservoir remains a critical challenge to inform strategies towards HIV cure. This proposal leverages three positron emission tomography-magnetic resonance (PET-MR) imaging clinical studies of radiolabeled raltegravir (RAL), broadly neutralizing antibody VRC01, and a non-specific marker of T cell activation (F-AraG) that allow us to visualize:
-
Application of quantitative intersectionality methods to identify the most vulnerable populations in the HIV continuum of care
Application of quantitative intersectionality methods to identify the most vulnerable populations in the HIV continuum of care
Abstract
People with severe mental illness (e.g., schizophrenia, bipolar disorder; SMI) are a socially marginalized population with up to ten times increased likelihood of being diagnosed with HIV compared to the general US population. The parent grant (R01-MH112420) aims to investigate the increased HIV transmission risk, low testing rate, and potential HIV treatment gaps for people with SMI using a large, geographically diverse national retrospective longitudinal Medicaid cohort.
-
Weight gain and metabolic consequences of switch to dolutegravir in Western Kenya
Weight gain and metabolic consequences of switch to dolutegravir in Western Kenya
Abstract
Dolutegravir was recently recommended as a component of first-line antiretroviral therapy (ART) for all adults living with HIV by the World Health Organization due to improved efficacy and tolerability over prior regimens. However, recent studies, including two randomized trials in sub-Saharan Africa, have shown significant weight gain associated with dolutegravir among ART-naïve patients newly initiating dolutegravir. It is not known whether switch to dolutegravir among ART-experienced patients will result in similar weight gain.
-
Potent Anti-HIV Gene Editing in Primary Myeloid Cells using CRISPR-Cas9 Technology
Potent Anti-HIV Gene Editing in Primary Myeloid Cells using CRISPR-Cas9 Technology
Abstract
Although HIV eradication efforts have mainly focused on latently-infected CD4+ T cells, myeloid cells harbor virus during suppressive antiretroviral therapy and participate in HIV dissemination and persistence. Infection of monocytes and macrophages contributes to inflammation and HIV-associated neurocognitive disorder (HAND). CRISPR/Cas9-mediated anti-HIV gene editing has been applied to excise HIV provirus and knock out the CXCR4 and CCR5 HIV co-receptors in CD4+ T cells as a cure approach. However, anti-HIV gene editing in the myeloid compartment has not been reported as yet. -
Assessing CSF HIV antibodies and CNS HIV viral reservoirs in HIV-Associated Neurocognitive Disorder (HAND)
Assessing CSF HIV antibodies and CNS HIV viral reservoirs in HIV-Associated Neurocognitive Disorder (HAND)
Abstract
Levels of cerebrospinal fluid (CSF) HIV antibodies are theorized as a broad marker of central nervous system (CNS) HIV reservoir size. In the proposed work, I will determine CSF HIV antibody levels and their antigenic targets in virally suppressed HIV+ elders with (n=30) and without (n=15) HIV-associated neurocognitive disorder (HAND).
-
Surface engineering of exosomes to specifically bind and kill HIV-infected cells
Surface engineering of exosomes to specifically bind and kill HIV-infected cells
Abstract
The current limitations of antiretroviral therapy is driving interest in alternative therapeutics which fully resolve inflammation and achieve complete eradication of HIV latently-infected cells. Exosomes are nano-sized membrane vesicles and key players of intercellular signaling. Interestingly, exosomes have shown promise as engineerable therapeutic agents for a broad range of diseases. The objective of this grant is to surface engineer exosomes ex vivo using surface display technology and pack the decorated exosomes with cytotoxic cargo.
-
Linkages between gender-based violence and engagement in HIV care in a prospective cohort of U.S. women living with HIV
Linkages between gender-based violence and engagement in HIV care in a prospective cohort of U.S. women living with HIV
Abstract
Evidence is mounting that gender-based violence (GBV) is a major barrier to engagement in HIV care and treatment, and viral suppression. Research has documented the powerful role of GBV on ART uptake and adherence, including a meta-analysis showing that intimate partner violence had a larger effect on adherence than other factors such as stigma, financial constraints, and pill burden. Yet four key gaps in knowledge remain.
-
Improving urine-based tuberculosis diagnosis in people living with HIV
Improving urine-based tuberculosis diagnosis in people living with HIV
Abstract
Tuberculosis (TB) is the leading cause of mortality in people living with HIV. To reduce the burden of disease, a non-sputum biomarker-based diagnostic for tuberculosis (TB) is urgently needed. Urine-based testing is promising, but current assays that detect the Mycobacterium tuberculosis (MTB) antigen lipoarabinomannan (LAM) have poor performance and are only recommended in HIV-infected individuals who are severely ill or have advanced AIDS. There is a need to improve the sensitivity of these assays, and for approaches to detect other low abundant TB biomarkers in urine.